These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19006671)

  • 1. Structure-activity relationship studies of a new series of imidazo[2,1-f]purinones as potent and selective A(3) adenosine receptor antagonists.
    Baraldi PG; Preti D; Tabrizi MA; Romagnoli R; Saponaro G; Baraldi S; Botta M; Bernardini C; Tafi A; Tuccinardi T; Martinelli A; Varani K; Borea PA
    Bioorg Med Chem; 2008 Dec; 16(24):10281-94. PubMed ID: 19006671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists.
    Baraldi PG; Preti D; Tabrizi MA; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Merighi S; Varani K; Borea PA
    J Med Chem; 2005 Jul; 48(14):4697-701. PubMed ID: 16000006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding.
    Priego EM; Pérez-Pérez MJ; von Frijtag Drabbe Kuenzel JK; de Vries H; Ijzerman AP; Camarasa MJ; Martín-Santamaría S
    ChemMedChem; 2008 Jan; 3(1):111-9. PubMed ID: 18000937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.
    Colotta V; Catarzi D; Varano F; Calabri FR; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Deflorian F; Moro S
    J Med Chem; 2004 Jul; 47(14):3580-90. PubMed ID: 15214785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrido[2,1-f]purine-2,4-dione derivatives as a novel class of highly potent human A(3) adenosine receptor antagonists.
    Priego EM; von Frijtag Drabbe Kuenzel J; IJzerman AP; Camarasa MJ; Pérez-Pérez MJ
    J Med Chem; 2002 Aug; 45(16):3337-44. PubMed ID: 12139445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and SAR studies of trisubstituted purinones as potent and selective adenosine A2A receptor antagonists.
    Shao Y; Cole AG; Brescia MR; Qin LY; Duo J; Stauffer TM; Rokosz LL; McGuinness BF; Henderson I
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1399-402. PubMed ID: 19181527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2,9-disubstituted-N6-(arylcarbamoyl)-8-azaadenines as new selective A3 adenosine receptor antagonists: synthesis, biochemical and molecular modelling studies.
    Biagi G; Bianucci AM; Coi A; Costa B; Fabbrini L; Giorgi I; Livi O; Micco I; Pacchini F; Santini E; Leonardi M; Nofal FA; Salerni OL; Scartoni V
    Bioorg Med Chem; 2005 Aug; 13(15):4679-93. PubMed ID: 15908217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists.
    Cosimelli B; Greco G; Ehlardo M; Novellino E; Da Settimo F; Taliani S; La Motta C; Bellandi M; Tuccinardi T; Martinelli A; Ciampi O; Trincavelli ML; Martini C
    J Med Chem; 2008 Mar; 51(6):1764-70. PubMed ID: 18269230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor model.
    Tuccinardi T; Schenone S; Bondavalli F; Brullo C; Bruno O; Mosti L; Zizzari AT; Tintori C; Manetti F; Ciampi O; Trincavelli ML; Martini C; Martinelli A; Botta M
    ChemMedChem; 2008 Jun; 3(6):898-913. PubMed ID: 18338422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
    Lenzi O; Colotta V; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Varani K; Marighetti F; Morizzo E; Moro S
    J Med Chem; 2006 Jun; 49(13):3916-25. PubMed ID: 16789747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists.
    Chang LC; von Frijtag Drabbe Künzel JK; Mulder-Krieger T; Westerhout J; Spangenberg T; Brussee J; Ijzerman AP
    J Med Chem; 2007 Feb; 50(4):828-34. PubMed ID: 17300165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.
    Lenzi O; Colotta V; Catarzi D; Varano F; Poli D; Filacchioni G; Varani K; Vincenzi F; Borea PA; Paoletta S; Morizzo E; Moro S
    J Med Chem; 2009 Dec; 52(23):7640-52. PubMed ID: 19743865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
    Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
    J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.
    Da Settimo F; Primofiore G; Taliani S; Marini AM; La Motta C; Simorini F; Salerno S; Sergianni V; Tuccinardi T; Martinelli A; Cosimelli B; Greco G; Novellino E; Ciampi O; Trincavelli ML; Martini C
    J Med Chem; 2007 Nov; 50(23):5676-84. PubMed ID: 17927167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QSAR of adenosine receptor antagonists. Part 3: Exploring physicochemical requirements for selective binding of 1,2,4-triazolo[5,1-i]purine derivatives with human adenosine A3 receptor subtype.
    Roy K; Leonard JT; Sengupta C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3705-9. PubMed ID: 15203147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models.
    Tafi A; Bernardini C; Botta M; Corelli F; Andreini M; Martinelli A; Ortore G; Baraldi PG; Fruttarolo F; Borea PA; Tuccinardi T
    J Med Chem; 2006 Jul; 49(14):4085-97. PubMed ID: 16821770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Varani K; Borea PA
    J Med Chem; 2005 Jul; 48(15):5001-8. PubMed ID: 16033279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
    Colotta V; Catarzi D; Varano F; Capelli F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Pedata F; Schiesaro A; Morizzo E; Moro S
    J Med Chem; 2007 Aug; 50(17):4061-74. PubMed ID: 17665891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists.
    Müller CE; Thorand M; Qurishi R; Diekmann M; Jacobson KA; Padgett WL; Daly JW
    J Med Chem; 2002 Aug; 45(16):3440-50. PubMed ID: 12139454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor.
    Volpini R; Dal Ben D; Lambertucci C; Taffi S; Vittori S; Klotz KN; Cristalli G
    J Med Chem; 2007 Mar; 50(6):1222-30. PubMed ID: 17309246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.